Biomaterials for direct cardiac repair-A rapid scoping review
2012-2022

J 2024

Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022

SEDLÁKOVÁ, Veronika, Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI et. al.

Základní údaje

Originální název

Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022

Autoři

SEDLÁKOVÁ, Veronika (203 Česká republika, domácí), Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI, Irene GUZMAN-SOTO, Marc RUEL, Erik SUURONEN a Emilio I ALARCON

Vydání

ACTA BIOMATERIALIA, London, ELSEVIER SCI LTD, 2024, 1742-7061

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 9.700 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.actbio.2024.04.008

UT WoS

001240708500001

Klíčová slova anglicky

Heart disease; Clinical trial; Scoping review; Multi-database searching

Štítky

14110517, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 7. 2024 09:31, Mgr. Tereza Miškechová

Anotace

V originále

A plethora of biomaterials for heart repair are being tested worldwide for potential clinical application. These therapeutics aim to enhance the quality of life of patients with heart disease using various methods to improve cardiac function. Despite the myriad of therapeutics tested, only a minority of these studied biomaterials have entered clinical trials. This rapid scoping review aims to analyze literature available from 2012 to 2022 with a focus on clinical trials using biomaterials for direct cardiac repair, i.e., where the intended function of the biomaterial is to enhance the repair of the endocardium, myocardium, epicardium or pericardium. This review included neither biomaterials related to stents and valve repair nor biomaterials serving as vehicles for the delivery of drugs. Surprisingly, the literature search revealed that only 8 different biomaterials mentioned in 23 different studies out of 7038 documents (journal articles, conference abstracts or clinical trial entries) have been tested in clinical trials since 2012. All of these, intended to treat various forms of ischaemic heart disease (heart failure, myocardial infarction), were of natural origin and most used direct injections as their delivery method. This review thus reveals notable gaps between groups of biomaterials tested pre-clinically and clinically.

Citovat

SEDLÁKOVÁ, Veronika, Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI, Irene GUZMAN-SOTO, Marc RUEL, Erik SUURONEN a Emilio I ALARCON. Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022. ACTA BIOMATERIALIA. London: ELSEVIER SCI LTD, 2024, roč. 180, May 2024, s. 61-81. ISSN 1742-7061. Dostupné z: https://dx.doi.org/10.1016/j.actbio.2024.04.008.

@article{2403757,
   author = {Sedláková, Veronika and Mourcos, Sophia and Pupkaitė, Justina and Lunn, Yvonne and Visintini, Sarah and GuzmanandSoto, Irene and Ruel, Marc and Suuronen, Erik and Alarcon, Emilio I},
   article_location = {London},
   article_number = {May 2024},
   doi = {http://dx.doi.org/10.1016/j.actbio.2024.04.008},
   keywords = {Heart disease; Clinical trial; Scoping review; Multi-database searching},
   language = {eng},
   issn = {1742-7061},
   journal = {ACTA BIOMATERIALIA},
   title = {Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022},
   url = {https://www.sciencedirect.com/science/article/pii/S1742706124001818},
   volume = {180},
   year = {2024}
}

TY  - JOUR
ID  - 2403757
AU  - Sedláková, Veronika - Mourcos, Sophia - Pupkaitė, Justina - Lunn, Yvonne - Visintini, Sarah - Guzman-Soto, Irene - Ruel, Marc - Suuronen, Erik - Alarcon, Emilio I
PY  - 2024
TI  - Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022
JF  - ACTA BIOMATERIALIA
VL  - 180
IS  - May 2024
SP  - 61-81
EP  - 61-81
PB  - ELSEVIER SCI LTD
SN  - 17427061
KW  - Heart disease
KW  - Clinical trial
KW  - Scoping review
KW  - Multi-database searching
UR  - https://www.sciencedirect.com/science/article/pii/S1742706124001818
N2  - A plethora of biomaterials for heart repair are being tested worldwide for potential clinical application. These therapeutics aim to enhance the quality of life of patients with heart disease using various methods to improve cardiac function. Despite the myriad of therapeutics tested, only a minority of these studied biomaterials have entered clinical trials. This rapid scoping review aims to analyze literature available from 2012 to 2022 with a focus on clinical trials using biomaterials for direct cardiac repair, i.e., where the intended function of the biomaterial is to enhance the repair of the endocardium, myocardium, epicardium or pericardium. This review included neither biomaterials related to stents and valve repair nor biomaterials serving as vehicles for the delivery of drugs. Surprisingly, the literature search revealed that only 8 different biomaterials mentioned in 23 different studies out of 7038 documents (journal articles, conference abstracts or clinical trial entries) have been tested in clinical trials since 2012. All of these, intended to treat various forms of ischaemic heart disease (heart failure, myocardial infarction), were of natural origin and most used direct injections as their delivery method. This review thus reveals notable gaps between groups of biomaterials tested pre-clinically and clinically.
ER  -

SEDLÁKOVÁ, Veronika, Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI, Irene GUZMAN-SOTO, Marc RUEL, Erik SUURONEN a Emilio I ALARCON. Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022. \textit{ACTA BIOMATERIALIA}. London: ELSEVIER SCI LTD, 2024, roč.~180, May 2024, s.~61-81. ISSN~1742-7061. Dostupné z: https://dx.doi.org/10.1016/j.actbio.2024.04.008.

Podrobný výpis o publikaci